ProKidney Statistics
 Total Valuation
 ProKidney has a market cap or net worth of $909.42 million. The enterprise value is $619.11 million.
 Important Dates
 The next estimated earnings date is Wednesday, November 12, 2025, before market open.
 | Earnings Date | Nov 12, 2025 | 
| Ex-Dividend Date | n/a | 
Share Statistics
 ProKidney has 295.27 million shares outstanding. The number of shares has increased by 102.08% in one year.
 | Current Share Class | 135.98M | 
| Shares Outstanding | 295.27M | 
| Shares Change (YoY) | +102.08% | 
| Shares Change (QoQ) | +1.36% | 
| Owned by Insiders (%) | 18.54% | 
| Owned by Institutions (%) | 16.52% | 
| Float | 86.72M | 
Valuation Ratios
  | PE Ratio | n/a | 
| Forward PE | n/a | 
| PS Ratio | 1,725.66 | 
| Forward PS | n/a | 
| PB Ratio | 2.68 | 
| P/TBV Ratio | n/a | 
| P/FCF Ratio | n/a | 
| P/OCF Ratio | n/a | 
| PEG Ratio | n/a | 
 Financial Ratio HistoryEnterprise Valuation
  | EV / Earnings | n/a | 
| EV / Sales | 1,174.79 | 
| EV / EBITDA | n/a | 
| EV / EBIT | n/a | 
| EV / FCF | n/a | 
Financial Position
 The company has a current ratio of 11.48, with a Debt / Equity ratio of 0.01.
 | Current Ratio | 11.48 | 
| Quick Ratio | 10.49 | 
| Debt / Equity | 0.01 | 
| Debt / EBITDA | n/a | 
| Debt / FCF | n/a | 
| Interest Coverage | -35,263.40 | 
Financial Efficiency
 Return on equity (ROE) is -40.51% and return on invested capital (ROIC) is -26.78%.
 | Return on Equity (ROE) | -40.51% | 
| Return on Assets (ROA) | -25.30% | 
| Return on Invested Capital (ROIC) | -26.78% | 
| Return on Capital Employed (ROCE) | -51.27% | 
| Revenue Per Employee | $2,583 | 
| Profits Per Employee | -$355,265 | 
| Employee Count | 204 | 
| Asset Turnover | 0.00 | 
| Inventory Turnover | n/a | 
Taxes
 In the past 12 months, ProKidney has paid $799,000 in taxes.
 | Income Tax | 799,000 | 
| Effective Tax Rate | n/a | 
Stock Price Statistics
 The stock price has increased by +79.07% in the last 52 weeks. The beta is 1.77, so ProKidney's price volatility has been higher than the market average.
 | Beta (5Y) | 1.77 | 
| 52-Week Price Change | +79.07% | 
| 50-Day Moving Average | 2.73 | 
| 200-Day Moving Average | 1.78 | 
| Relative Strength Index (RSI) | 53.37 | 
| Average Volume (20 Days) | 2,242,739 | 
Short Selling Information
 The latest short interest is 10.74 million, so 3.64% of the outstanding shares have been sold short.
 | Short Interest | 10.74M | 
| Short Previous Month | 10.71M | 
| Short % of Shares Out | 3.64% | 
| Short % of Float | 12.38% | 
| Short Ratio (days to cover) | 5.20 | 
Income Statement
 In the last 12 months, ProKidney had revenue of $527,000 and -$72.47 million in losses. Loss per share was -$0.56.
 | Revenue | 527,000 | 
| Gross Profit | 527,000 | 
| Operating Income | -176.32M | 
| Pretax Income | -163.65M | 
| Net Income | -72.47M | 
| EBITDA | -170.19M | 
| EBIT | -176.32M | 
| Loss Per Share | -$0.56 | 
 Full Income StatementBalance Sheet
 The company has $294.73 million in cash and $4.42 million in debt, giving a net cash position of $290.31 million or $0.98 per share.
 | Cash & Cash Equivalents | 294.73M | 
| Total Debt | 4.42M | 
| Net Cash | 290.31M | 
| Net Cash Per Share | $0.98 | 
| Equity (Book Value) | 339.45M | 
| Book Value Per Share | -7.51 | 
| Working Capital | 296.18M | 
 Full Balance SheetCash Flow
 In the last 12 months, operating cash flow was -$114.42 million and capital expenditures -$32.16 million, giving a free cash flow of -$146.58 million.
 | Operating Cash Flow | -114.42M | 
| Capital Expenditures | -32.16M | 
| Free Cash Flow | -146.58M | 
| FCF Per Share | -$0.50 | 
 Full Cash Flow StatementMargins
  | Gross Margin | 100.00% | 
| Operating Margin | -33,456.74% | 
| Pretax Margin | -31,053.89% | 
| Profit Margin | n/a | 
| EBITDA Margin | n/a | 
| EBIT Margin | n/a | 
| FCF Margin | n/a | 
Dividends & Yields
 ProKidney does not appear to pay any dividends at this time.
 | Dividend Per Share | n/a | 
| Dividend Yield | n/a | 
| Dividend Growth (YoY) | n/a | 
| Years of Dividend Growth | n/a | 
| Payout Ratio | n/a | 
| Buyback Yield | -102.08% | 
| Shareholder Yield | -102.08% | 
| Earnings Yield | -7.97% | 
| FCF Yield | -16.12% | 
 Dividend DetailsAnalyst Forecast
 The average price target for ProKidney is $6.25, which is 102.92% higher than the current price. The consensus rating is "Strong Buy".
 | Price Target | $6.25 | 
| Price Target Difference | 102.92% | 
| Analyst Consensus | Strong Buy | 
| Analyst Count | 4 | 
| Revenue Growth Forecast (5Y) | 440.09% | 
| EPS Growth Forecast (5Y) | -16.41% | 
 Stock ForecastsFair Value
 There are several formulas that can be used to estimate the intrinsic value of a stock.
 | Lynch Fair Value | n/a | 
| Lynch Upside | n/a | 
| Graham Number | n/a | 
| Graham Upside | n/a | 
Stock Splits
 This stock does not have any record of stock splits.
 | Last Split Date | n/a | 
| Split Type | n/a | 
| Split Ratio | n/a | 
Scores
 ProKidney has an Altman Z-Score of -1.62. A Z-score under 3 suggests an increased risk of bankruptcy.
 | Altman Z-Score | -1.62 | 
| Piotroski F-Score | n/a |